These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 7441795)

  • 21. Identification of an active acidic residue in the catalytic site of beta-hexosaminidase.
    Tse R; Vavougios G; Hou Y; Mahuran DJ
    Biochemistry; 1996 Jun; 35(23):7599-607. PubMed ID: 8652542
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Accumulation of ganglioside Gm2 in cerebrospinal fluid of a patient with the variant AB of infantile Gm2 gangliosidosis.
    Pullarkat RK; Reha H; Beratis NG
    Pediatrics; 1981 Jul; 68(1):106-8. PubMed ID: 7243492
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Restoration of the GM2 ganglioside metabolism in bone marrow-derived stromal cells from Tay-Sachs disease animal model.
    Martino S; Cavalieri C; Emiliani C; Dolcetta D; Cusella De Angelis MG; Chigorno V; Severini GM; Sandhoff K; Bordignon C; Sonnino S; Orlacchio A
    Neurochem Res; 2002 Aug; 27(7-8):793-800. PubMed ID: 12374215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GM2-ganglioside metabolism in hexosaminidase A deficiency states: determination in situ using labeled GM2 added to fibroblast cultures.
    Raghavan SS; Krusell A; Krusell J; Lyerla TA; Kolodny EH
    Am J Hum Genet; 1985 Nov; 37(6):1071-82. PubMed ID: 2934978
    [TBL] [Abstract][Full Text] [Related]  

  • 25. GM2 ganglioside in fetal Tay-Sachs disease brain cultures: a model system for the disease.
    Hoffman LM; Amsterdam D; Schneck L
    Brain Res; 1976 Jul; 111(1):109-17. PubMed ID: 953690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sialidase-mediated depletion of GM2 ganglioside in Tay-Sachs neuroglia cells.
    Igdoura SA; Mertineit C; Trasler JM; Gravel RA
    Hum Mol Genet; 1999 Jun; 8(6):1111-6. PubMed ID: 10332044
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Biosynthesis and biodegradation of GM2 ganglioside].
    Hirabayashi Y; Kasakura H; Matsumoto M
    Tanpakushitsu Kakusan Koso; 1984 Sep; 29(9):708-22. PubMed ID: 6240072
    [No Abstract]   [Full Text] [Related]  

  • 28. Effect of modification of sialic acid on enzymic hydrolysis of gangliosides GM1 and GM2.
    Li SC; Serizawa S; Li YT; Nakamura K; Handa S
    J Biol Chem; 1984 May; 259(9):5409-10. PubMed ID: 6232275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism.
    Sango K; Yamanaka S; Hoffmann A; Okuda Y; Grinberg A; Westphal H; McDonald MP; Crawley JN; Sandhoff K; Suzuki K; Proia RL
    Nat Genet; 1995 Oct; 11(2):170-6. PubMed ID: 7550345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ganglioside GM2 N-acetyl-beta-D-galactosaminidase and asialo GM2 (GA2) N-acetyl-beta-D-galactosaminidase; studies in human skin fibroblasts.
    O'Brien JS; Norden GW; Miller AL; Frost RG; Kelly TE
    Clin Genet; 1977 Mar; 11(3):171-83. PubMed ID: 13950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis of novel NBD-GM1 and NBD-GM2 for the transfer activity of GM2-activator protein by a FRET-based assay system.
    Schwarzmann G; Wendeler M; Sandhoff K
    Glycobiology; 2005 Dec; 15(12):1302-11. PubMed ID: 16079415
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin.
    Platt FM; Neises GR; Reinkensmeier G; Townsend MJ; Perry VH; Proia RL; Winchester B; Dwek RA; Butters TD
    Science; 1997 Apr; 276(5311):428-31. PubMed ID: 9103204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deficiency of the hexosaminidase A activator protein in a case of GM2 gangliosidosis; variant AB.
    Hechtman P; Gordon BA; Ng Ying Kin NM
    Pediatr Res; 1982 Mar; 16(3):217-22. PubMed ID: 6801612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel Vector Design and Hexosaminidase Variant Enabling Self-Complementary Adeno-Associated Virus for the Treatment of Tay-Sachs Disease.
    Karumuthil-Melethil S; Nagabhushan Kalburgi S; Thompson P; Tropak M; Kaytor MD; Keimel JG; Mark BL; Mahuran D; Walia JS; Gray SJ
    Hum Gene Ther; 2016 Jul; 27(7):509-21. PubMed ID: 27197548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neurophysiological investigations in GM1 and GM2 gangliosidoses.
    Pampiglione G; Harden A
    Neuropediatrics; 1984 Sep; 15 Suppl():74-84. PubMed ID: 6100798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mice deficient in Neu4 sialidase exhibit abnormal ganglioside catabolism and lysosomal storage.
    Seyrantepe V; Canuel M; Carpentier S; Landry K; Durand S; Liang F; Zeng J; Caqueret A; Gravel RA; Marchesini S; Zwingmann C; Michaud J; Morales CR; Levade T; Pshezhetsky AV
    Hum Mol Genet; 2008 Jun; 17(11):1556-68. PubMed ID: 18270209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prenatal diagnosis of Sandhoff's disease (GM2-gangliosidosis, type 2)].
    Harzer K; Stengel-Rutkowski S; Gley EO; Albert A; Murken JD; Zahn V; Henkel KP
    Dtsch Med Wochenschr; 1975 Jan; 100(3):106-8. PubMed ID: 234374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Juvenile GM2 gangliosidosis (AMB variant): inability to activate hexosaminidase A by activator protein.
    Inui K; Grebner EE; Jackson LG; Wenger DA
    Am J Hum Genet; 1983 Jul; 35(4):551-64. PubMed ID: 6224417
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of an activating factor required for hydrolysis of Gm2 ganglioside catalyzed by hexosaminidase A.
    Hechtman P
    Can J Biochem; 1977 Apr; 55(4):315-24. PubMed ID: 858083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Morphology of the gangliosidoses.
    Goebel HH
    Neuropediatrics; 1984 Sep; 15 Suppl():97-106. PubMed ID: 6100800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.